<DOC>
	<DOCNO>NCT01858740</DOCNO>
	<brief_summary>This phase II trial study well T cell deplete donor peripheral blood stem cell transplant work prevent graft-versus-host disease young patient high risk hematologic malignancy . Giving chemotherapy total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Removing subset T cell donor cell transplant may stop happening .</brief_summary>
	<brief_title>Selective Depletion CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts Preventing GVHD Children</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Estimate time discontinuation systemic immunosuppression pediatric recipient cluster differentiation 45RA positive ( CD45RA+ ) T cell-depleted peripheral blood stem cell transplant ( PBSCT ) . II . Estimate probability graft failure pediatric recipient CD45RA+ T-cell-depleted PBSCT . SECONDARY OBJECTIVES : I . Estimate compare appropriate historical cohort probability chronic graft-versus-host disease ( GVHD ) ( National Institutes Health [ NIH ] criterion ) require treatment systemic pharmacological immunosuppression pediatric patient receive CD45RA+ T cell deplete PBSC . II . Estimate probability acute GVHD grade II-IV . III . Estimate probability steroid refractory acute GVHD . IV . Evaluate immune reconstitution . V. Estimate probability transplant-related mortality day 100 . VI . Estimate probability relapse . OUTLINE : CONDITIONING REGIMEN : Patients undergo total body irradiation ( TBI ) twice daily ( BID ) day -10 -7 , receive thiotepa intravenously ( IV ) 4 hour day -6 -5 fludarabine phosphate IV 30 minute day -6 -2 . TRANSPLANT : Patients undergo CD34+ enrich , CD45RA+ T cell-depleted allogeneic PBSCT day 0 . POST-TRANSPLANT IMMUNOSUPPRESSION : Patients receive tacrolimus IV continuously orally ( PO ) every 12 hour begin day -1 continue day 50 taper . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Biphenotypic , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients consider appropriate candidate allogeneic hematopoietic stem cell transplantation one follow diagnosis : Acute lymphocytic leukemia first subsequent remission Acute myeloid leukemia first subsequent remission Acute lymphocytic leukemia relapse primary refractory disease circulate blast count 10,000/mm^3 Acute myeloid leukemia relapse primary refractory disease circulate blast count 10,000/mm^3 Refractory anemia excess blast ( RAEB1 RAEB2 ) Chronic myelogenous leukemia history accelerate phase blast crisis Other acute leukemia ( include limit 'biphenotypic ' , 'undifferentiated ' 'ambiguous lineage ' acute leukemia ) Patient human leukocyte antigen ( HLA ) identical ( HLAA , B , C , ribonucleic acid [ RNA ] bind motif protein 45 [ DRB1 ] molecularly match ) unrelated donor relate donor capable donate PBSC DONOR : HLAmatched unrelated donor ( HLAA , B , C , DRB1 match base highresolution type ) capable willing donate PBSC DONOR : HLAmatched relate donor &gt; = 18 year capable willing donate PBSC Patients central nervous system ( CNS ) involvement refractory intrathecal chemotherapy and/or standard cranialspinal radiation Patients experimental protocols prevention acute GVHD Patients weigh &gt; = 70 kg must discuss principal investigator prior enrol protocol Patients human immunodeficiency virus positive ( HIV+ ) Patients uncontrolled infection myeloablative hematopoietic stem cell transplant ( HCT ) consider contraindicated consult infectious disease physician ( upper respiratory tract viral infection constitute uncontrolled infection context ) Creatinine &gt; 1.5 mg/dl Cardiac ejection fraction &lt; 45 % Patients perform pulmonary function test exclude diffuse capacity lung carbon monoxide ( DLCO ) ( correct hemoglobin ) &lt; 60 % predict ; patient unable perform pulmonary function test ( example , due young age and/or developmental status ) exclude oxygen ( O2 ) saturation &lt; 92 % room air Patients liver function test ( LFTs ) ( include total bilirubin , aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] ) &gt; = twice upper limit normal evaluate gastrointestinal ( GI ) physician unless clear precipitate factor ( azole , methotrexate , Bactrim another drug ) ; GI physician considers HCT protocol 2660 contraindicate patient patient exclude protocol ; patient Gilbert 's syndrome know liver function abnormality patient reversible drugrelated transaminitis necessarily require GI consultation may include protocol Patients life expectancy &lt; 3 month coexist disease leukemia RAEB Patients pregnant breastfeed Fertile patient child bearing age unwilling use contraception 12 month posttransplant Patients significant medical condition would make unsuitable transplant Patients know hypersensitivity tacrolimus DONOR : Donors HIV1 , HIV2 , human Tlymphotropic virus ( HTLV ) 1 , HTLV2 seropositive active hepatitis B hepatitis C virus infection DONOR : Donors fail eligibility requirement donation cell tissue per section 21 Code Federal Regulations ( CFR ) 1271 donation HCT/product ( P ) exclude unless use cell comply 21 CFR 1271.65 ( b ) ( iii ) ( urgent medical need ) 21 CFR 1271.65 ( b ) ( ) ( allogeneic use firstdegree seconddegree relative ) DONOR : Unrelated donor donate outside United States America ( USA ) Germany</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>